Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants

This Phase 2a clinical trial, completed in 2024, investigated the efficacy, safety, and tolerability of DFV890 and MAS825 for reducing inflammatory markers in adults with coronary heart disease and clonal hematopoiesis of indeterminate potential (CHIP). The study was a multi-center, randomized, placebo-controlled, participant- and investigator-blinded design. The target population was approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP, defined by a variant allele frequency (VAF) of 2% or greater. The actual enrollment was 31 participants. The intervention involved increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single subcutaneous dose of MAS825. Participants were randomized to one of five treatment sequences, starting on Day 1 with either a combination of MAS825 and placebo, DFV890 and placebo, or placebo and placebo. Within each DFV890 treatment sequence, participants received up-titrated doses. The study structure included a screening period of up to 30 days, a treatment period of approximately 12 weeks with an end-of-treatment visit on Day 85, a follow-up period of approximately 1 week, and a safety follow-up call approximately 30 days after the last dose, resulting in an overall study duration of approximately 21 weeks. The primary outcomes were the ratio to baseline serum levels of IL-6 for DFV890 based on an Emax model, the ratio to baseline serum levels of IL-18 for DFV890 based on an Emax model, and the ratio to baseline serum levels of IL-6 for MAS825 based on a traditional linear regression model. The abstract does not report specific numerical results for these efficacy outcomes, safety signals, or study limitations.

If you have coronary heart disease and a blood condition called clonal hematopoiesis of indeterminate potential (CHIP), your body may be stuck in a state of harmful, chronic inflammation. This inflammation, driven by proteins like IL-6 and IL-18, is thought to fuel further heart damage. A recent clinical trial asked a direct question: can we safely turn down that inflammatory fire? The study tested two experimental drugs—DFV890, taken as a daily pill for 12 weeks, and MAS825, given as a single injection—in approximately 28 adults who had both heart disease and specific types of CHIP. The goal was to see if these treatments could reduce levels of IL-6 and IL-18, which are key markers of cardiovascular risk. This was a carefully controlled study where participants were randomly assigned to receive one of the drugs or a placebo, and neither they nor their doctors knew which they got. The main outcomes measured were how much the drugs changed the levels of these inflammation markers from the start of the study. While the abstract doesn't give the final results, the core finding is that researchers have completed a direct test of whether targeting these specific inflammatory pathways is a viable approach for this high-risk group of patients. The answer to that question could reshape how we think about treating heart disease when it's intertwined with CHIP.